Trial record 1 of 1 for:
Phase II single arm study testing SBRT, Adenosine signaling Modulation (AB680, AB928), and Immune Checkpoint inhibition (AB122) for men with hormone sensitive Oligometastatic prostate cancer (SBRT-AMICO)
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05915442 |
Recruitment Status :
Recruiting
First Posted : June 23, 2023
Last Update Posted : May 7, 2024
|
Sponsor:
Catherine Spina
Collaborator:
Arcus Biosciences, Inc.
Information provided by (Responsible Party):
Catherine Spina, Columbia University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | December 1, 2025 |
Estimated Study Completion Date : | December 2028 |